Skip to main content
    T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $78.20
    -0.48 (-0.61%)

    Market Cap: $3.88B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Tarsus Pharmaceuticals Inc (TARS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Tarsus Pharmaceuticals (TARS) has a market cap of $3.88B and an enterprise value of $3.82B. It kept -102.93% of revenue as net income over the last 12 months. Revenue grew 86.34% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 1.64% below the market cap, as cash exceeds debt.

    Market Cap$3.88B
    Enterprise Value$3.82B
    Latest price (Nov 17, 2026)$78.20

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.98% in the quarter ended Sep 30, 2026 and grew 9.98% a year over 2 years.

    Shares Outstanding46.42M
    Shares Change (YoY)+8.95%
    Shares Change (QoQ)+6.98%
    Share Count Growth (2Y CAGR)+9.98%

    Valuation Ratios

    Sales and book value multiples are 5.3x and 34.9x. Its year-end P/S ranged from 7.6x to 35.9x from 2021 to 2025.

    P/S Ratio5.3x
    Forward P/S5.2x
    P/B Ratio34.9x
    P/TBV Ratio41.5x
    P/FCF Ratio111.9x
    P/OCF Ratio77.7x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 109.9x free cash flow.

    EV / Sales5.6x
    EV / FCF109.9x

    Price Statistics

    The stock is up 7.24% over 52 weeks and trades 5.08% above its 50-day average.

    Beta (1Y)0.60
    52-Week Change+7.24%
    1-Month Change+12.52%
    3-Month Change+6.48%
    6-Month Change+27.59%
    5-Year Change+169.63%
    Total Return (1Y)+7.24%
    Total Return (3Y CAGR)+60.64%
    Total Return (5Y CAGR)+25.49%
    Return vs SPY (1Y)-9.96%
    Max Drawdown (1Y)-32.00%
    Max Drawdown (3Y)-45.08%
    Sharpe Ratio (1Y)0.04
    Correlation with SPY (1Y)0.18
    50-Day Average$74.42
    200-Day Average$68.10
    52-Week Range$53.89 to $91.53
    RSI (14 Days)59.6
    Average Volume (20 Days)849.95K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.96x current liabilities, and total debt is 0.70x shareholder equity.

    Current Ratio1.96x
    Quick Ratio1.94x
    Debt / Equity0.70x
    Debt / FCF2.25x
    Interest Coverage-80.21x

    Returns and Efficiency

    Return on invested capital is -393.56% over the last 12 months, against a 5-year average of -17.11%.

    Return on Equity (ROE)-675.03%
    Return on Assets (ROA)-138.92%
    Return on Invested Capital (ROIC)-393.56%
    ROE (5Y Average)-36.05%
    ROA (5Y Average)-25.73%
    ROIC (5Y Average)-17.11%
    Asset Turnover1.31x
    Inventory Turnover9.72x
    Receivables Turnover6.81x
    Cash Conversion Cycle-1314 days

    Scores

    TARS has an Altman Z-Score of -0.36, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.36
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $682.20M over the last 12 months.

    Revenue$682.20M
    Revenue Growth (YoY)+86.34%
    Gross Profit$635.87M
    Operating Income-$696.10M
    Pretax Income-$690.46M
    Net Income-$702.23M
    Reported EPS (TTM)-$1.57

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 20.58% of the $505.50M in total assets.

    Cash and Equivalents$136.53M
    Total Debt$72.94M
    Net Cash$63.59M
    Net Cash Per Share$1.37
    Working Capital$218.30M
    Shareholder Equity$104.03M
    Book Value Per Share$2.24
    Tangible Book Value$87.38M
    Tangible Book Per Share$1.88
    Total Assets$505.50M
    Total Liabilities$401.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $17.46M of capital spending, operating cash flow left $32.44M of free cash flow.

    Operating Cash Flow$49.90M
    Capital Expenditures$17.46M
    Free Cash Flow$32.44M
    FCF Per Share$0.69
    Depreciation and Amortization$3.31M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -102.04%.

    Gross Margin93.21%
    Operating Margin-102.04%
    Pretax Margin-101.21%
    Net Margin-102.93%
    FCF Margin4.76%
    Gross Margin (5Y Average)93.94%

    Growth

    Revenue grew 159.54% a year over 3 years.

    Revenue Growth (3Y CAGR)+159.54%
    Book Value Per Share Growth (2Y CAGR)+14.09%
    Tangible Book Per Share Growth (2Y CAGR)+13.98%

    Revenue and profit by year

    Dividends and Yields

    TARS does not pay a dividend. Its free cash flow yield is 0.89%.

    FCF Yield0.89%
    Buyback Yield-3.39%
    Shareholder Yield-3.39%

    Peer Position

    Against 7 similar companies, TARS has the 4th highest P/S.

    P/S Ratio5.3x vs 5.2x median
    ROIC-393.56% vs -26.18% median
    Revenue Growth (Trailing 4 Quarters, YoY)+86.34% vs -21.78% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 43.96% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+43.96%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TARS

    What is TARS's market cap?

    Tarsus Pharmaceuticals has a market cap of $3.88B. Its enterprise value, which adds debt and subtracts cash, is $3.82B.

    How many shares of TARS are outstanding?

    Tarsus Pharmaceuticals has 46.42M shares outstanding. The count is up 8.95% from a year earlier.

    Does TARS pay a dividend?

    No. Tarsus Pharmaceuticals does not pay a dividend.

    How much debt does TARS have?

    Tarsus Pharmaceuticals has $72.94M of total debt and $136.53M of cash and equivalents, a net cash position of $63.59M.